Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
|Articles|May 9, 2018
What if Every Prescription Drug Came with an Amazon Alexa?
Author(s)Michelle Maskaly
Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Advertisement
Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.
His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Advertisement
Related to this article
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
4
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
5